04.29.24
Hypha Labs Inc., which recently changed its name from Digipath Inc. after the sale of its cannabis lab assets, has appointed Craig Ellins as its Chief Science Officer.
Hypha Labs has developed cutting-edge technology focused on new methods of producing the active ingredients found in functional mushrooms such as psilocybin using its patent pending bioreactor design.
According to the company, Ellins is “a visionary in emerging technologies and industries,” having founded and led companies like One World Pharma and GB Sciences. He boasts expertise in identifying and capitalizing on early-stage opportunities in new markets and is especially knowledgeable about the cannabis industry, which the company believes the psilocybin space will mirror.
Hypha Labs has developed cutting-edge technology focused on new methods of producing the active ingredients found in functional mushrooms such as psilocybin using its patent pending bioreactor design.
According to the company, Ellins is “a visionary in emerging technologies and industries,” having founded and led companies like One World Pharma and GB Sciences. He boasts expertise in identifying and capitalizing on early-stage opportunities in new markets and is especially knowledgeable about the cannabis industry, which the company believes the psilocybin space will mirror.